BRAF inhibitor therapy for melanoma, thyroid and colorectal cancers: Development of resistance and future prospects

Current Cancer Drug Targets

Volumn 14, Issue 2, 2014, Pages 128-143

  Rahman, Md Atiqur ^a   Salajegheh, Ali ^a   Smith, Robert Anthony ^a   Lam, Alfred King yin ^a  

^a GRIFFITH UNIVERSITY   (Australia)

Author keywords

BRAF; Gene therapy; Kinase inhibitors; Treatment resistance

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ABC TRANSPORTER; AZ 628; B RAF KINASE; CETUXIMAB; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; DABRAFENIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GSK 2126458; HER3 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; RAF PROTEIN; RAPAMYCIN; REGORAFENIB; SCATTER FACTOR; SELUMETINIB; SMALL INTERFERING RNA; SOMATOMEDIN C RECEPTOR; SORAFENIB; TRAMETINIB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VEMURAFENIB; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

ANGIOGENESIS; APOPTOSIS; CARCINOGENESIS; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL CANCER; COLORECTAL CARCINOMA; DIMERIZATION; GENE MUTATION; GENE THERAPY; GENETIC TRANSCRIPTION; HUMAN; LIVER CELL CARCINOMA; MELANOMA; METASTATIC MELANOMA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN PHOSPHORYLATION; REVIEW; RNA INTERFERENCE; THYROID CANCER; ANIMAL; ANTAGONISTS AND INHIBITORS; COLORECTAL NEOPLASMS; DRUG DESIGN; DRUG EFFECTS; DRUG RESISTANCE; ENZYMOLOGY; FORECASTING; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROCEDURES; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; THYROID NEOPLASMS; TRENDS;

ANIMALS; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; FORECASTING; GENETIC THERAPY; HUMANS; MELANOMA; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; THYROID NEOPLASMS;

EID: 84896361648     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/1568009614666140121150930     Document Type: Review

References (165)

1. Moelling, K.; Heimann, B.; Beimling, P.; Rapp, U. R.; Sander, T. Serine-and threonine-specific protein kinase activities of purified gag-mil and gag-raf proteins. Nature 1984, 312 (5994), 558-561.
2. Rapp, U. R.; Goldsborough, M. D.; Mark, G. E.; Bonner, T. I.; Groffen, J.; Reynolds, F. H., Jr.; Stephenson, J. R. Structure and biological activity of v-raf, a unique oncogene transduced by a retrovirus. Proc. Natl. Acad. Sci. U.S.A. 1983, 80 (14), 4218-4222.
3. Zebisch, A.; Troppmair, J. Back to the roots: the remarkable RAF oncogene story. Cell Mol. Life. Sci. 2006, 63 (11), 1314-1330.
4. Rahman, M. A.; Salajegheh, A.; Smith, R. A.; Lam, A. K. Y. B-Raf mutation: A key player in molecular biology of cancer. Exp. Mol. Pathol. 2013, 95 (3), 336-342.
5. Bonner, T. I.; Kerby, S. B.; Sutrave, P.; Gunnell, M. A.; Mark, G.; Rapp, U. R. Structure and biological activity of human homologs of the raf/mil oncogene. Mol. Cell. Biol. 1985, 5 (6), 1400-1407.
6. Huebner, K.; ar-Rushdi, A.; Griffin, C. A.; Isobe, M.; Kozak, C.; Emanuel, B. S.; Nagarajan, L.; Cleveland, J. L.; Bonner, T. I.; Goldsborough, M. D.; et al. Actively transcribed genes in the raf oncogene group, located on the X chromosome in mouse and human. Proc. Natl. Acad. Sci. U.S.A. 1986, 83 (11), 3934-3938.
7. Ikawa, S.; Fukui, M.; Ueyama, Y.; Tamaoki, N.; Yamamoto, T.; Toyoshima, K. B-raf, a new member of the raf family, is activated by DNA rearrangement. Mol. Cell Biol. 1988, 8 (6), 2651-2654.
8. Roskoski, J. R. RAF protein-serine/threonine kinases: structure and regulation. Biochem. Biophys. Res. Commun. 2010, 399 (3), 313-317.
9. Cantwell-Dorris, E. R.; O'Leary, J. J.; Sheils, O. M. BRAFV600E: implications for carcinogenesis and molecular therapy. Mol. Cancer. Ther. 2011, 10 (3), 385-394.
10. Garnett, M. J.; Marais, R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell 2004, 6 (4), 313-319.
11. Davies, H.; Bignell, G. R.; Cox, C.; Stephens, P.; Edkins, S.; Clegg, S.; Teague, J.; Woffendin, H.; Garnett, M. J.; Bottomley, W.; Davis, N.; Dicks, E.; Ewing, R.; Floyd, Y.; Gray, K.; Hall, S.; Hawes, R.; Hughes, J.; Kosmidou, V.; Menzies, A.; Mould, C.; Parker, A.; Stevens, C.; Watt, S.; Hooper, S.; Wilson, R.; Jayatilake, H.; Gusterson, B. A.; Cooper, C.; Shipley, J.; Hargrave, D.; Pritchard-Jones, K.; Maitland, N.; Chenevix-Trench, G.; Riggins, G. J.; Bigner, D. D.; Palmieri, G.; Cossu, A.; Flanagan, A.; Nicholson, A.; Ho, J. W.; Leung, S. Y.; Yuen, S. T.; Weber, B. L.; Seigler, H. F.; Darrow, T. L.; Paterson, H.; Marais, R.; Marshall, C. J.; Wooster, R.; Stratton, M. R.; Futreal, P. A. Mutations of the BRAF gene in human cancer. Nature 2002, 417 (6892), 949-954.
12. Xing, M. BRAF mutation in thyroid cancer. Endocr. Relat. Cancer 2005, 12 (2), 245-262.
13. Jakob, J. A.; Bassett, R. L., Jr.; Ng, C. S.; Curry, J. L.; Joseph, R. W.; Alvarado, G. C.; Rohlfs, M. L.; Richard, J.; Gershenwald, J. E.; Kim, K. B.; Lazar, A. J.; Hwu, P.; Davies, M. A. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 2012, 118 (16), 4014-4023.
14. Smith, R. A.; Salajegheh, A.; Weinstein, S.; Nassiri, M.; Lam, A. K. Correlation between BRAF mutation and the clinicopathological parameters in papillary thyroid carcinoma with particular reference to follicular variant. Hum. Pathol. 2011, 42 (4), 500-506.
15. Pakneshan, S.; Salajegheh, A.; Smith, R. A.; Lam, A. K. Clinicopathological relevance of BRAF mutations in human cancer. Pathology 2013, 45 (4), 346-356.
16. Long, G. V.; Menzies, A. M.; Nagrial, A. M.; Haydu, L. E.; Hamilton, A. L.; Mann, G. J.; Hughes, T. M.; Thompson, J. F.; Scolyer, R. A.; Kefford, R. F. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J. Clin. Oncol. 2011, 29 (10), 1239-1246.
17. Kim, T. H.; Park, Y. J.; Lim, J. A.; Ahn, H. Y.; Lee, E. K.; Lee, Y. J.; Kim, K. W.; Hahn, S. K.; Youn, Y. K.; Kim, K. H.; Cho, B. Y.; Park do, J. The association of the BRAF (V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer 2012, 118 (7), 1764-1773.
18. El-Osta, H.; Falchook, G.; Tsimberidou, A.; Hong, D.; Naing, A.; Kim, K.; Wen, S.; Janku, F.; Kurzrock, R. BRAF mutations in advanced cancers: clinical characteristics and outcomes. PLoS One 2011, 6 (10), e25806.
19. Lee, S.; Cho, N. Y.; Choi, M.; Yoo, E. J.; Kim, J. H.; Kang, G. H. Clinicopathological features of CpG island methylator phenotypepositive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation. Pathol. Int. 2008, 58 (2), 104-113.
20. Wan, P. T.; Garnett, M. J.; Roe, S. M.; Lee, S.; Niculescu-Duvaz, D.; Good, V. M.; Jones, C. M.; Marshall, C. J.; Springer, C. J.; Barford, D.; Marais, R. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004, 116 (6), 855-867.
21. Zambon, A.; Niculescu-Duvaz, I.; Niculescu-Duvaz, D.; Marais, R.; Springer, C. J. Small molecule inhibitors of BRAF in clinical trials. Bioorg. Med. Chem. Lett. 2012, 22 (2), 789-792.
22. Zhang, J.; Yang, P. L.; Gray, N. S. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer 2009, 9 (1), 28-39.
23. Ribas, A.; Flaherty, K. T. BRAF targeted therapy changes the treatment paradigm in melanoma. Nature reviews. Clin. Oncol. 2011, 8 (7), 426-433.
24. Menzies, A. M.; Long, G. V.; Murali, R. Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Des. Devel. Ther. 2012, 6, 391-405.
25. Mol, C. D.; Fabbro, D.; Hosfield, D. J. Structural insights into the conformational selectivity of STI-571 and related kinase inhibitors. Curr. Opin. Drug Discov. Devel. 2004, 7 (5), 639-648.
26. Pargellis, C.; Tong, L.; Churchill, L.; Cirillo, P. F.; Gilmore, T.; Graham, A. G.; Grob, P. M.; Hickey, E. R.; Moss, N.; Pav, S.; Regan, J. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat. Struct. Biol. 2002, 9 (4), 268-272.
27. Schindler, T.; Bornmann, W.; Pellicena, P.; Miller, W. T.; Clarkson, B.; Kuriyan, J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000, 289 (5486), 1938-1942.
28. Liu, Y.; Gray, N. S. Rational design of inhibitors that bind to inactive kinase conformations. Nat. Chem. Biol. 2006, 2 (7), 358-364.
29. Traxler, P.; Furet, P. Strategies toward the design of novel and selective protein tyrosine kinase inhibitors. Pharmacol. Ther. 1999, 82 (2-3), 195-206.
30. Chapman, P. B.; Hauschild, A.; Robert, C.; Haanen, J. B.; Ascierto, P.; Larkin, J.; Dummer, R.; Garbe, C.; Testori, A.; Maio, M.; Hogg, D.; Lorigan, P.; Lebbe, C.; Jouary, T.; Schadendorf, D.; Ribas, A.; O'Day, S. J.; Sosman, J. A.; Kirkwood, J. M.; Eggermont, A. M.; Dreno, B.; Nolop, K.; Li, J.; Nelson, B.; Hou, J.; Lee, R. J.; Flaherty, K. T.; McArthur, G. A. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 2011, 364 (26), 2507-2516.
31. da Rocha Dias, S.; Salmonson, T.; van Zwieten-Boot, B.; Jonsson, B.; Marchetti, S.; Schellens, J. H.; Giuliani, R.; Pignatti, F. The European Medicines Agency review of vemurafenib (Zelboraf(R) for the treatment of adult patients with BRAF V600 mutationpositive unresectable or metastatic melanoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use. Eur. J. Cancer 2013, 49 (7), 1654-1661.
32. Hauschild, A.; Grob, J. J.; Demidov, L. V.; Jouary, T.; Gutzmer, R.; Millward, M.; Rutkowski, P.; Blank, C. U.; Miller, W. H., Jr.; Kaempgen, E.; Martin-Algarra, S.; Karaszewska, B.; Mauch, C.; Chiarion-Sileni, V.; Martin, A. M.; Swann, S.; Haney, P.; Mirakhur, B.; Guckert, M. E.; Goodman, V.; Chapman, P. B. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012, 380 (9839), 358-365.
33. Llovet, J. M.; Ricci, S.; Mazzaferro, V.; Hilgard, P.; Gane, E.; Blanc, J. F.; de Oliveira, A. C.; Santoro, A.; Raoul, J. L.; Forner, A.; Schwartz, M.; Porta, C.; Zeuzem, S.; Bolondi, L.; Greten, T. F.; Galle, P. R.; Seitz, J. F.; Borbath, I.; Haussinger, D.; Giannaris, T.; Shan, M.; Moscovici, M.; Voliotis, D.; Bruix, J. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008, 359 (4), 378-390.
34. Grothey, A.; Van Cutsem, E.; Sobrero, A.; Siena, S.; Falcone, A.; Ychou, M.; Humblet, Y.; Bouche, O.; Mineur, L.; Barone, C.; Adenis, A.; Tabernero, J.; Yoshino, T.; Lenz, H. J.; Goldberg, R. M.; Sargent, D. J.; Cihon, F.; Cupit, L.; Wagner, A.; Laurent, D. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013, 381 (9863), 303-312.
35. Rahman, M. A.; Salajegheh, A.; Smith, R. A.; Lam, A. K. BRAF inhibitors: From the laboratory to clinical trials. Crit. Rev. Oncol. Hematol. 2013, http://dx.doi.org/10.1016/j.critrevonc.2013.12.008 (In Press).
36. Nathanson, K. L.; Martin, A.; Letrero, R.; D'Andrea, K. P.; O'Day, S. J.; Infante, J. R.; Falchook, G. S.; Millward, M.; Curtis, C. M.; Ma, B.; Gagnon, R. C.; Lebowitz, P. F.; Long, G. V.; Kefford, R. F. Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor GSK2118436 (GSK436). J. Clin. Oncol. 2011, 29, (suppl; abstr 8501).
37. Smalley, K. S.; Lioni, M.; Dalla Palma, M.; Xiao, M.; Desai, B.; Egyhazi, S.; Hansson, J.; Wu, H.; King, A. J.; Van Belle, P.; Elder, D. E.; Flaherty, K. T.; Herlyn, M.; Nathanson, K. L. Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol. Cancer Ther. 2008, 7 (9), 2876-2883.
38. Straussman, R.; Morikawa, T.; Shee, K.; Barzily-Rokni, M.; Qian, Z. R.; Du, J.; Davis, A.; Mongare, M. M.; Gould, J.; Frederick, D. T.; Cooper, Z. A.; Chapman, P. B.; Solit, D. B.; Ribas, A.; Lo, R. S.; Flaherty, K. T.; Ogino, S.; Wargo, J. A.; Golub, T. R. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012, 487 (7408), 500-504.
39. Wilson, T. R.; Fridlyand, J.; Yan, Y.; Penuel, E.; Burton, L.; Chan, E.; Peng, J.; Lin, E.; Wang, Y.; Sosman, J.; Ribas, A.; Li, J.; Moffat, J.; Sutherlin, D. P.; Koeppen, H.; Merchant, M.; Neve, R.; Settleman, J. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012, 487 (7408), 505-509.
40. Baldin, V.; Lukas, J.; Marcote, M. J.; Pagano, M.; Draetta, G. Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev. 1993, 7 (5), 812-821.
41. Sherr, C. J. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res. 2000, 60 (14), 3689-3695.
42. Fu, M.; Wang, C.; Li, Z.; Sakamaki, T.; Pestell, R. G. Minireview: Cyclin D1: normal and abnormal functions. Endocrinology 2004, 145 (12), 5439-5447.
43. Hinds, P. W.; Dowdy, S. F.; Eaton, E. N.; Arnold, A.; Weinberg, R. A. Function of a human cyclin gene as an oncogene. Proc. Natl. Acad. Sci. U. S.A. 1994, 91 (2), 709-713.
44. Robles, A. I.; Rodriguez-Puebla, M. L.; Glick, A. B.; Trempus, C.; Hansen, L.; Sicinski, P.; Tennant, R. W.; Weinberg, R. A.; Yuspa, S. H.; Conti, C. J. Reduced skin tumor development in cyclin D1-deficient mice highlights the oncogenic ras pathway in vivo. Genes Dev. 1998, 12 (16), 2469-2474.
45. Lovec, H.; Sewing, A.; Lucibello, F. C.; Muller, R.; Moroy, T. Oncogenic activity of cyclin D1 revealed through cooperation with Ha-ras: link between cell cycle control and malignant transformation. Oncogene 1994, 9 (1), 323-326.
46. Paraiso, K. H.; Xiang, Y.; Rebecca, V. W.; Abel, E. V.; Chen, Y. A.; Munko, A. C.; Wood, E.; Fedorenko, I. V.; Sondak, V. K.; Anderson, A. R.; Ribas, A.; Palma, M. D.; Nathanson, K. L.; Koomen, J. M.; Messina, J. L.; Smalley, K. S. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res. 2011, 71 (7), 2750-2760.
47. Sansal, I.; Sellers, W. R. The biology and clinical relevance of the PTEN tumor suppressor pathway. J. Clin. Oncol. 2004, 22 (14), 2954-2963.
48. Alqurashi, N.; Gopalan, V.; Smith, R. A.; Lam, A. K. Clinical impacts of mammalian target of rapamycin expression in human colorectal cancers. Hum. Pathol. 2013, 44 (10), 2089-2096.
49. Montagut, C.; Sharma, S. V.; Shioda, T.; McDermott, U.; Ulman, M.; Ulkus, L. E.; Dias-Santagata, D.; Stubbs, H.; Lee, D. Y.; Singh, A.; Drew, L.; Haber, D. A.; Settleman, J. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res. 2008, 68 (12), 4853-4861.
50. Poulikakos, P. I.; Persaud, Y.; Janakiraman, M.; Kong, X.; Ng, C.; Moriceau, G.; Shi, H.; Atefi, M.; Titz, B.; Gabay, M. T.; Salton, M.; Dahlman, K. B.; Tadi, M.; Wargo, J. A.; Flaherty, K. T.; Kelley, M. C.; Misteli, T.; Chapman, P. B.; Sosman, J. A.; Graeber, T. G.; Ribas, A.; Lo, R. S.; Rosen, N.; Solit, D. B. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011, 480 (7377), 387-390.
51. Shi, H.; Moriceau, G.; Kong, X.; Lee, M. K.; Lee, H.; Koya, R. C.; Ng, C.; Chodon, T.; Scolyer, R. A.; Dahlman, K. B.; Sosman, J. A.; Kefford, R. F.; Long, G. V.; Nelson, S. F.; Ribas, A.; Lo, R. S. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat. Commun. 2012, 3, 724.
52. Nazarian, R.; Shi, H.; Wang, Q.; Kong, X.; Koya, R. C.; Lee, H.; Chen, Z.; Lee, M. K.; Attar, N.; Sazegar, H.; Chodon, T.; Nelson, S. F.; McArthur, G.; Sosman, J. A.; Ribas, A.; Lo, R. S. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010, 468 (7326), 973-977.
53. Emery, C. M.; Vijayendran, K. G.; Zipser, M. C.; Sawyer, A. M.; Niu, L.; Kim, J. J.; Hatton, C.; Chopra, R.; Oberholzer, P. A.; Karpova, M. B.; MacConaill, L. E.; Zhang, J.; Gray, N. S.; Sellers, W. R.; Dummer, R.; Garraway, L. A. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc. Natl. Acad. Sci. U.S.A. 2009, 106 (48), 20411-20416.
54. Johannessen, C. M.; Boehm, J. S.; Kim, S. Y.; Thomas, S. R.; Wardwell, L.; Johnson, L. A.; Emery, C. M.; Stransky, N.; Cogdill, A. P.; Barretina, J.; Caponigro, G.; Hieronymus, H.; Murray, R. R.; Salehi-Ashtiani, K.; Hill, D. E.; Vidal, M.; Zhao, J. J.; Yang, X.; Alkan, O.; Kim, S.; Harris, J. L.; Wilson, C. J.; Myer, V. E.; Finan, P. M.; Root, D. E.; Roberts, T. M.; Golub, T.; Flaherty, K. T.; Dummer, R.; Weber, B. L.; Sellers, W. R.; Schlegel, R.; Wargo, J. A.; Hahn, W. C.; Garraway, L. A. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010, 468 (7326), 968-972.
55. Poulikakos, P. I.; Zhang, C.; Bollag, G.; Shokat, K. M.; Rosen, N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010, 464 (7287), 427-430.
56. Wagle, N.; Emery, C.; Berger, M. F.; Davis, M. J.; Sawyer, A.; Pochanard, P.; Kehoe, S. M.; Johannessen, C. M.; Macconaill, L. E.; Hahn, W. C.; Meyerson, M.; Garraway, L. A. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J. Clin. Oncol. 2011, 29 (22), 3085-3096.
57. Corcoran, R. B.; Settleman, J.; Engelman, J. A. Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers. Oncotarget. 2011, 2 (4), 336-346.
58. Trunzer, K.; Pavlick, A. C.; Schuchter, L.; Gonzalez, R.; McArthur, G. A.; Hutson, T. E.; Moschos, S. J.; Flaherty, K. T.; Kim, K. B.; Weber, J. S.; Hersey, P.; Long, G. V.; Lawrence, D.; Ott, P. A.; Amaravadi, R. K.; Lewis, K. D.; Puzanov, I.; Lo, R. S.; Koehler, A.; Kockx, M.; Spleiss, O.; Schell-Steven, A.; Gilbert, H. N.; Cockey, L.; Bollag, G.; Lee, R. J.; Joe, A. K.; Sosman, J. A.; Ribas, A. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J. Clin. Oncol. 2013, 31 (14), 1767-1774.
59. Dumaz, N.; Hayward, R.; Martin, J.; Ogilvie, L.; Hedley, D.; Curtin, J. A.; Bastian, B. C.; Springer, C.; Marais, R. In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res. 2006, 66 (19), 9483-9491.
60. Antony, R.; Emery, C. M.; Sawyer, A. M.; Garraway, L. A. C-RAF mutations confer resistance to RAF inhibitors. Cancer Res. 2013, 73 (15), 4840-4851.
61. Lito, P.; Pratilas, C. A.; Joseph, E. W.; Tadi, M.; Halilovic, E.; Zubrowski, M.; Huang, A.; Wong, W. L.; Callahan, M. K.; Merghoub, T.; Wolchok, J. D.; de Stanchina, E.; Chandarlapaty, S.; Poulikakos, P. I.; Fagin, J. A.; Rosen, N. Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell 2012, 22 (5), 668-682.
62. Girotti, M. R.; Marais, R. Deja Vu: EGF receptors drive resistance to BRAF inhibitors. Cancer Discov. 2013, 3 (5), 487-490.
63. Prahallad, A.; Sun, C.; Huang, S.; Di Nicolantonio, F.; Salazar, R.; Zecchin, D.; Beijersbergen, R. L.; Bardelli, A.; Bernards, R. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012, 483 (7387), 100-103.
64. Corcoran, R. B.; Ebi, H.; Turke, A. B.; Coffee, E. M.; Nishino, M.; Cogdill, A. P.; Brown, R. D.; Della Pelle, P.; Dias-Santagata, D.; Hung, K. E.; Flaherty, K. T.; Piris, A.; Wargo, J. A.; Settleman, J.; Mino-Kenudson, M.; Engelman, J. A. EGFR-mediated reactivation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2012, 2 (3), 227-235.
65. Montero-Conde, C.; Ruiz-Llorente, S.; Dominguez, J. M.; Knauf, J. A.; Viale, A.; Sherman, E. J.; Ryder, M.; Ghossein, R. A.; Rosen, N.; Fagin, J. A. Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discov. 2013, 3 (5), 520-533.
66. Villanueva, J.; Vultur, A.; Lee, J. T.; Somasundaram, R.; Fukunaga-Kalabis, M.; Cipolla, A. K.; Wubbenhorst, B.; Xu, X.; Gimotty, P. A.; Kee, D.; Santiago-Walker, A. E.; Letrero, R.; D'Andrea, K.; Pushparajan, A.; Hayden, J. E.; Brown, K. D.; Laquerre, S.; McArthur, G. A.; Sosman, J. A.; Nathanson, K. L.; Herlyn, M. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010, 18 (6), 683-695.
67. Girotti, M. R.; Pedersen, M.; Sanchez-Laorden, B.; Viros, A.; Turajlic, S.; Niculescu-Duvaz, D.; Zambon, A.; Sinclair, J.; Hayes, A.; Gore, M.; Lorigan, P.; Springer, C.; Larkin, J.; Jorgensen, C.; Marais, R. Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov. 2013, 3 (2), 158-167.
68. Olayioye, M. A.; Beuvink, I.; Horsch, K.; Daly, J. M.; Hynes, N. E. ErbB receptor-induced activation of stat transcription factors is mediated by Src tyrosine kinases. J. Biol. Chem. 1999, 274 (24), 17209-17218.
69. Wu, C. P.; Sim, H. M.; Huang, Y. H.; Liu, Y. C.; Hsiao, S. H.; Cheng, H. W.; Li, Y. Q.; Ambudkar, S. V.; Hsu, S. C. Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells. Biochem. Pharmacol. 2013, 85 (3), 325-334.
70. Smalley, K. S.; Haass, N. K.; Brafford, P. A.; Lioni, M.; Flaherty, K. T.; Herlyn, M. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol. Cancer Ther. 2006, 5 (5), 1136-1144.
71. Greger, J. G.; Eastman, S. D.; Zhang, V.; Bleam, M. R.; Hughes, A. M.; Smitheman, K. N.; Dickerson, S. H.; Laquerre, S. G.; Liu, L.; Gilmer, T. M. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol. Cancer Ther. 2012, 11 (4), 909-920.
72. Jin, N.; Jiang, T.; Rosen, D. M.; Nelkin, B. D.; Ball, D. W. Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer. J. Clin. Endocrinol. Metab. 2009, 94 (10), 4107-4112.
73. Liu, R.; Liu, D.; Xing, M. The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells. J. Clin. Endocrinol. Metab. 2012, 97 (2), E173-E182.
74. Flaherty, K. T.; Infante, J. R.; Daud, A.; Gonzalez, R.; Kefford, R. F.; Sosman, J.; Hamid, O.; Schuchter, L.; Cebon, J.; Ibrahim, N.; Kudchadkar, R.; Burris, H. A., 3rd; Falchook, G.; Algazi, A.; Lewis, K.; Long, G. V.; Puzanov, I.; Lebowitz, P.; Singh, A.; Little, S.; Sun, P.; Allred, A.; Ouellet, D.; Kim, K. B.; Patel, K.; Weber, J. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 2012, 367 (18), 1694-1703.
75. Gray-Schopfer, V. C.; Karasarides, M.; Hayward, R.; Marais, R. Tumor necrosis factor-alpha blocks apoptosis in melanoma cells when BRAF signaling is inhibited. Cancer Res. 2007, 67 (1), 122-129.
76. Brocker, E. B.; Zwadlo, G.; Holzmann, B.; Macher, E.; Sorg, C. Inflammatory cell infiltrates in human melanoma at different stages of tumor progression. Int. J. Cancer 1988, 41 (4), 562-567.
77. Torisu, H.; Ono, M.; Kiryu, H.; Furue, M.; Ohmoto, Y.; Nakayama, J.; Nishioka, Y.; Sone, S.; Kuwano, M. Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: possible involvement of TNFalpha and IL-1alpha. Int. J. Cancer 2000, 85 (2), 182-188.
78. Duncan, L. M.; Richards, L. A.; Mihm, M. C., Jr. Increased mast cell density in invasive melanoma. J. Cutan. Pathol. 1998, 25 (1), 11-15.
79. Amiri, K. I.; Richmond, A. Role of nuclear factor-kappa B in melanoma. Cancer Metastasis Rev. 2005, 24 (2), 301-313.
80. McNulty, S. E.; Tohidian, N. B.; Meyskens, F. L., Jr. RelA, p50 and inhibitor of kappa B alpha are elevated in human metastatic melanoma cells and respond aberrantly to ultraviolet light B. Pigment. Cell Res. 2001, 14 (6), 456-465.
81. Dhawan, P.; Richmond, A. A novel NF-kappa B-inducing kinase-MAPK signaling pathway up-regulates NF-kappa B activity in melanoma cells. J. Biol. Chem. 2002, 277 (10), 7920-7928.
82. McNulty, S. E.; del Rosario, R.; Cen, D.; Meyskens, F. L., Jr.; Yang, S. Comparative expression of NFkappaB proteins in melanocytes of normal skin vs. benign intradermal naevus and human metastatic melanoma biopsies. Pigment Cell Res. 2004, 17 (2), 173-180.
83. Pacifico, F.; Mauro, C.; Barone, C.; Crescenzi, E.; Mellone, S.; Monaco, M.; Chiappetta, G.; Terrazzano, G.; Liguoro, D.; Vito, P.; Consiglio, E.; Formisano, S.; Leonardi, A. Oncogenic and antiapoptotic activity of NF-kappa B in human thyroid carcinomas. J. Biol. Chem. 2004, 279 (52), 54610-54619.
84. Mitsiades, C. S.; McMillin, D.; Kotoula, V.; Poulaki, V.; McMullan, C.; Negri, J.; Fanourakis, G.; Tseleni-Balafouta, S.; Ain, K. B.; Mitsiades, N. Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro. J. Clin. Endocrinol. Metab. 2006, 91 (10), 4013-4021.
85. Visconti, R.; Cerutti, J.; Battista, S.; Fedele, M.; Trapasso, F.; Zeki, K.; Miano, M. P.; de Nigris, F.; Casalino, L.; Curcio, F.; Santoro, M.; Fusco, A. Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NFkappaB p65 protein expression. Oncogene 1997, 15 (16), 1987-1994.
86. Pacifico, F.; Leonardi, A. NF-kappaB in solid tumors. Biochem. Pharmacol. 2006, 72 (9), 1142-1152.
87. Garnett, M. J.; Rana, S.; Paterson, H.; Barford, D.; Marais, R. Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol. Cell 2005, 20 (6), 963-969.
88. Romashkova, J. A.; Makarov, S. S. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 1999, 401 (6748), 86-90.
89. Cox, A. D.; Der, C. J. The dark side of Ras: regulation of apoptosis. Oncogene 2003, 22 (56), 8999-9006.
90. Dhomen, N.; Marais, R. New insight into BRAF mutations in cancer. Curr. Opin. Genet. Dev. 2007, 17 (1), 31-39.
91. Li, X.; Stark, G. R. NFkappaB-dependent signaling pathways. Exp. Hematol. 2002, 30 (4), 285-296.
92. Sizemore, N.; Leung, S.; Stark, G. R. Activation of phosphatidylinositol 3-kinase in response to interleukin-1 leads to phosphorylation and activation of the NF-kappaB p65/RelA subunit. Mol. Cell Biol. 1999, 19 (7), 4798-4805.
93. Ozes, O. N.; Mayo, L. D.; Gustin, J. A.; Pfeffer, S. R.; Pfeffer, L. M.; Donner, D. B. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 1999, 401 (6748), 82-85.
94. Khwaja, A. Akt is more than just a Bad kinase. Nature 1999, 401 (6748), 33-34.
95. Koul, D.; Yao, Y.; Abbruzzese, J. L.; Yung, W. K.; Reddy, S. A. Tumor suppressor MMAC/PTEN inhibits cytokine-induced NFkappaB activation without interfering with the IkappaB degradation pathway. J. Biol. Chem. 2001, 276 (14), 11402-11408.
96. Madrid, L. V.; Mayo, M. W.; Reuther, J. Y.; Baldwin, A. S., Jr. Akt stimulates the transactivation potential of the RelA/p65 Subunit of NF-kappa B through utilization of the Ikappa B kinase and activation of the mitogen-activated protein kinase p38. J. Biol. Chem. 2001, 276 (22), 18934-18940.
97. Madrid, L. V.; Wang, C. Y.; Guttridge, D. C.; Schottelius, A. J.; Baldwin, A. S., Jr.; Mayo, M. W. Akt suppresses apoptosis by stimulating the transactivation potential of the RelA/p65 subunit of NF-kappaB. Mol. Cell. Biol. 2000, 20 (5), 1626-1638.
98. Kane, L. P.; Shapiro, V. S.; Stokoe, D.; Weiss, A. Induction of NFkappaB by the Akt/PKB kinase. Curr. Biol. 1999, 9 (11), 601-604.
99. Fire, A.; Xu, S.; Montgomery, M. K.; Kostas, S. A.; Driver, S. E.; Mello, C. C. Potent and specific genetic interference by doublestranded RNA in Caenorhabditis elegans. Nature 1998, 391 (6669), 806-811.
100. Izquierdo, M. Short interfering RNAs as a tool for cancer gene therapy. Cancer Gene Ther. 2005, 12 (3), 217-227.
101. Wang, Z.; Rao, D. D.; Senzer, N.; Nemunaitis, J. RNA interference and cancer therapy. Pharm. Res. 2011, 28 (12), 2983-2995.
102. Takeshita, F.; Ochiya, T. Therapeutic potential of RNA interference against cancer. Cancer Sci. 2006, 97 (8), 689-696.
103. Nykanen, A.; Haley, B.; Zamore, P. D. ATP requirements and small interfering RNA structure in the RNA interference pathway. Cell 2001, 107 (3), 309-321.
104. Schwarz, D. S.; Hutvagner, G.; Haley, B.; Zamore, P. D. Evidence that siRNAs function as guides, not primers, in the Drosophila and human RNAi pathways. Mol. Cell 2002, 10 (3), 537-548.
105. Elbashir, S. M.; Lendeckel, W.; Tuschl, T. RNA interference is mediated by 21-and 22-nucleotide RNAs. Genes Dev. 2001, 15 (2), 188-200.
106. Bertrand, J. R.; Pottier, M.; Vekris, A.; Opolon, P.; Maksimenko, A.; Malvy, C. Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem. Biophys. Res. Commun. 2002, 296 (4), 1000-1004.
107. Davis, M. E.; Zuckerman, J. E.; Choi, C. H.; Seligson, D.; Tolcher, A.; Alabi, C. A.; Yen, Y.; Heidel, J. D.; Ribas, A. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464 (7291), 1067-1070.
108. Cervantes, A.; Alsina, M.; Tabernero, J.; Infante, J. R.; LoRusso, P.; Shapiro, G.; Paz-Ares, L. G.; Falzone, R.; Hill, J.; Cehelsky, J.; White, A.; Toudjarska, I.; Bumcrot, D.; Meyers, R.; Hinkle, G.; Svrzikapa, N.; Sah, D. W.; Vaishnaw, A.; Gollob, J.; Burris, H. A. Phase I dose-escalation study of ALN-VSP02, a novel RNAi therapeutic for solid tumors with liver involvement. J. Clin. Oncol. 2011, 29 (suppl; abstr 3025).
109. Tabernero, J.; Shapiro, G. I.; LoRusso, P. M.; Cervantes, A.; Schwartz, G. K.; Weiss, G. J.; Paz-Ares, L.; Cho, D. C.; Infante, J. R.; Alsina, M.; Gounder, M. M.; Falzone, R.; Harrop, J.; White, A. C.; Toudjarska, I.; Bumcrot, D.; Meyers, R. E.; Hinkle, G.; Svrzikapa, N.; Hutabarat, R. M.; Clausen, V. A.; Cehelsky, J.; Nochur, S. V.; Gamba-Vitalo, C.; Vaishnaw, A. K.; Sah, D. W.; Gollob, J. A.; Burris, H. A., 3rd First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov. 2013, 3 (4), 406-417.
110. Patnaik, A.; Chiorean, E. G.; Tolcher, A.; Papadopoulos, K.; Beeram, M.; Kee, D.; Waddell, M.; Gilles, E.; Buchbinder, A. EZN-2968, a novel hypoxia-inducible factor-1α (HIF-1α) messenger ribonucleic acid (mRNA) antagonist: Results of a phase I, pharmacokinetic (PK), dose-escalation study of daily administration in patients (pts) with advanced malignancies.c. J. Clin. Oncol. 2009, 27 (15s), (suppl; abstr 2564).
111. Burnett, J. C.; Rossi, J. J.; Tiemann, K. Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol. J. 2011, 6 (9), 1130-1146.
112. Rao, D. D.; Maples, P. B.; Senzer, N.; Kumar, P.; Wang, Z.; Pappen, B. O.; Yu, Y.; Haddock, C.; Jay, C.; Phadke, A. P.; Chen, S.; Kuhn, J.; Dylewski, D.; Scott, S.; Monsma, D.; Webb, C.; Tong, A.; Shanahan, D.; Nemunaitis, J. Enhanced target gene knockdown by a bifunctional shRNA: a novel approach of RNA interference. Cancer Gene Ther. 2010, 17 (11), 780-791.
113. Tiemann, K.; Hohn, B.; Ehsani, A.; Forman, S. J.; Rossi, J. J.; Saetrom, P. Dual-targeting siRNAs. RNA. 2010, 16 (6), 1275-1284.
114. Rao, D. D.; Vorhies, J. S.; Senzer, N.; Nemunaitis, J. siRNA vs. shRNA: similarities and differences. Adv. Drug Deliv. Rev. 2009, 61 (9), 746-759.
115. Phadke, A. P.; Jay, C. M.; Wang, Z.; Chen, S.; Liu, S.; Haddock, C.; Kumar, P.; Pappen, B. O.; Rao, D. D.; Templeton, N. S.; Daniels, E. Q.; Webb, C.; Monsma, D.; Scott, S.; Dylewski, D.; Frieboes, H. B.; Brunicardi, F. C.; Senzer, N.; Maples, P. B.; Nemunaitis, J.; Tong, A. W. In vivo safety and antitumor efficacy of bifunctional small hairpin RNAs specific for the human Stathmin 1 oncoprotein. DNA Cell Biol. 2011, 30 (9), 715-726.
116. Senzer, N.; Barve, M.; Kuhn, J.; Melnyk, A.; Beitsch, P.; Lazar, M.; Lifshitz, S.; Magee, M.; Oh, J.; Mill, S. W.; Bedell, C.; Higgs, C.; Kumar, P.; Yu, Y.; Norvell, F.; Phalon, C.; Taquet, N.; Rao, D. D.; Wang, Z.; Jay, C. M.; Pappen, B. O.; Wallraven, G.; Brunicardi, F. C.; Shanahan, D. M.; Maples, P. B.; Nemunaitis, J. Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer. Mol. Ther. 2012, 20 (3), 679-686.
117. Lee, R. C.; Feinbaum, R. L.; Ambros, V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993, 75 (5), 843-854.
118. Wightman, B.; Ha, I.; Ruvkun, G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 1993, 75 (5), 855-862.
119. Esquela-Kerscher, A.; Slack, F. J. Oncomirs-microRNAs with a role in cancer. Nat. Rev. Cancer 2006, 6 (4), 259-269.
120. Lu, M.; Zhang, Q.; Deng, M.; Miao, J.; Guo, Y.; Gao, W.; Cui, Q. An analysis of human microRNA and disease associations. PLoS ONE 2008, 3 (10), e3420.
121. Ambros, V. The functions of animal microRNAs. Nature 2004, 431 (7006), 350-355.
122. Stefani, G.; Slack, F. J. Small non-coding RNAs in animal development. Nat. Rev. Mol. Cell Biol. 2008, 9 (3), 219-230.
123. Foshay, K. M.; Gallicano, G. I. Small RNAs, big potential: the role of MicroRNAs in stem cell function. Curr. Stem Cell Res. Ther. 2007, 2 (4), 264-271.
124. Taganov, K. D.; Boldin, M. P.; Baltimore, D. MicroRNAs and immunity: tiny players in a big field. Immunity 2007, 26 (2), 133-137.
125. Wilfred, B. R.; Wang, W. X.; Nelson, P. T. Energizing miRNA research: a review of the role of miRNAs in lipid metabolism, with a prediction that miR-103/107 regulates human metabolic pathways. Mol. Genet. Metab. 2007, 91 (3), 209-217.
126. Lindsay, M. A. microRNAs and the immune response. Trends. Immunol. 2008, 29 (7), 343-351.
127. Blakaj, A.; Lin, H. Piecing together the mosaic of early mammalian development through microRNAs. J. Biol. Chem. 2008, 283 (15), 9505-9508.
128. Krutzfeldt, J.; Stoffel, M. MicroRNAs: a new class of regulatory genes affecting metabolism. Cell Metab. 2006, 4 (1), 9-12.
129. Boehm, M.; Slack, F. J. MicroRNA control of lifespan and metabolism. Cell Cycle 2006, 5 (8), 837-840.
130. Xiao, C.; Rajewsky, K. MicroRNA control in the immune system: basic principles. Cell 2009, 136 (1), 26-36.
131. Ibanez-Ventoso, C.; Yang, M.; Guo, S.; Robins, H.; Padgett, R. W.; Driscoll, M. Modulated microRNA expression during adult lifespan in Caenorhabditis elegans. Aging Cell 2006, 5 (3), 235-246.
132. Krol, J.; Loedige, I.; Filipowicz, W. The widespread regulation of microRNA biogenesis, function and decay. Nat. Rev. Genet. 2010, 11 (9), 597-610.
133. Zhao, Y.; Srivastava, D. A developmental view of microRNA function. Trends Biochem. Sci. 2007, 32 (4), 189-197.
134. Borchert, G. M.; Lanier, W.; Davidson, B. L. RNA polymerase III transcribes human microRNAs. Nat. Struct. Mol. Biol. 2006, 13 (12), 1097-1101.
135. Kim, V. N.; Nam, J. W. Genomics of microRNA. Trends Genet. 2006, 22 (3), 165-173.
136. He, L.; Hannon, G. J. MicroRNAs: small RNAs with a big role in gene regulation. Nat. Rev. Genet. 2004, 5 (7), 522-531.
137. Lee, Y.; Ahn, C.; Han, J.; Choi, H.; Kim, J.; Yim, J.; Lee, J.; Provost, P.; Radmark, O.; Kim, S.; Kim, V. N. The nuclear RNase III Drosha initiates microRNA processing. Nature 2003, 425 (6956), 415-419.
138. Bernstein, E.; Caudy, A. A.; Hammond, S. M.; Hannon, G. J. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 2001, 409 (6818), 363-366.
139. Zhang, H.; Kolb, F. A.; Brondani, V.; Billy, E.; Filipowicz, W. Human Dicer preferentially cleaves dsRNAs at their termini without a requirement for ATP. EMBO J. 2002, 21 (21), 5875-5885.
140. John, B.; Enright, A. J.; Aravin, A.; Tuschl, T.; Sander, C.; Marks, D. S. Human MicroRNA targets. PLoS Biol. 2004, 2 (11), e363.
141. Bartel, D. P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116 (2), 281-297.
142. Gartel, A. L.; Kandel, E. S. miRNAs: Little known mediators of oncogenesis. Semin. Cancer Biol. 2008, 18 (2), 103-110.
143. Tay, Y.; Zhang, J.; Thomson, A. M.; Lim, B.; Rigoutsos, I. MicroRNAs to Nanog, Oct4 and Sox2 coding regions modulate embryonic stem cell differentiation. Nature 2008, 455 (7216), 1124-1128.
144. Lytle, J. R.; Yario, T. A.; Steitz, J. A. Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5' UTR as in the 3' UTR. Proc. Natl. Acad. Sci. U.S.A. 2007, 104 (23), 9667-9672.
145. Liu, X.; Sempere, L. F.; Galimberti, F.; Freemantle, S. J.; Black, C.; Dragnev, K. H.; Ma, Y.; Fiering, S.; Memoli, V.; Li, H.; DiRenzo, J.; Korc, M.; Cole, C. N.; Bak, M.; Kauppinen, S.; Dmitrovsky, E. Uncovering growth-suppressive MicroRNAs in lung cancer. Clin. Cancer Res. 2009, 15 (4), 1177-1183.
146. Trang, P.; Wiggins, J. F.; Daige, C. L.; Cho, C.; Omotola, M.; Brown, D.; Weidhaas, J. B.; Bader, A. G.; Slack, F. J. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol. Ther. 2011, 19 (6), 1116-1122.
147. Liu, C.; Kelnar, K.; Liu, B.; Chen, X.; Calhoun-Davis, T.; Li, H.; Patrawala, L.; Yan, H.; Jeter, C.; Honorio, S.; Wiggins, J. F.; Bader, A. G.; Fagin, R.; Brown, D.; Tang, D. G. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat. Med. 2011, 17 (2), 211-215.
148. Takeshita, F.; Patrawala, L.; Osaki, M.; Takahashi, R. U.; Yamamoto, Y.; Kosaka, N.; Kawamata, M.; Kelnar, K.; Bader, A. G.; Brown, D.; Ochiya, T. Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol. Ther. 2010, 18 (1), 181-187.
149. Xu, D.; Takeshita, F.; Hino, Y.; Fukunaga, S.; Kudo, Y.; Tamaki, A.; Matsunaga, J.; Takahashi, R. U.; Takata, T.; Shimamoto, A.; Ochiya, T.; Tahara, H. miR-22 represses cancer progression by inducing cellular senescence. J. Cell Biol. 2011, 193 (2), 409-424.
150. Kota, J.; Chivukula, R. R.; O'Donnell, K. A.; Wentzel, E. A.; Montgomery, C. L.; Hwang, H. W.; Chang, T. C.; Vivekanandan, P.; Torbenson, M.; Clark, K. R.; Mendell, J. R.; Mendell, J. T. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009, 137 (6), 1005-1017.
151. Ma, L.; Reinhardt, F.; Pan, E.; Soutschek, J.; Bhat, B.; Marcusson, E. G.; Teruya-Feldstein, J.; Bell, G. W.; Weinberg, R. A. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat. Biotechnol. 2010, 28 (4), 341-347.
152. Bonauer, A.; Carmona, G.; Iwasaki, M.; Mione, M.; Koyanagi, M.; Fischer, A.; Burchfield, J.; Fox, H.; Doebele, C.; Ohtani, K.; Chavakis, E.; Potente, M.; Tjwa, M.; Urbich, C.; Zeiher, A. M.; Dimmeler, S. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science 2009, 324 (5935), 1710-1713.
153. Kumar, M. S.; Erkeland, S. J.; Pester, R. E.; Chen, C. Y.; Ebert, M. S.; Sharp, P. A.; Jacks, T. Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc. Natl. Acad. Sci. U.S.A. 2008, 105 (10), 3903-3908.
154. Esquela-Kerscher, A.; Trang, P.; Wiggins, J. F.; Patrawala, L.; Cheng, A.; Ford, L.; Weidhaas, J. B.; Brown, D.; Bader, A. G.; Slack, F. J. The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle 2008, 7 (6), 759-764.
155. Park, S. M.; Shell, S.; Radjabi, A. R.; Schickel, R.; Feig, C.; Boyerinas, B.; Dinulescu, D. M.; Lengyel, E.; Peter, M. E. Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGA2. Cell Cycle 2007, 6 (21), 2585-2590.
156. Silber, J.; Lim, D. A.; Petritsch, C.; Persson, A. I.; Maunakea, A. K.; Yu, M.; Vandenberg, S. R.; Ginzinger, D. G.; James, C. D.; Costello, J. F.; Bergers, G.; Weiss, W. A.; Alvarez-Buylla, A.; Hodgson, J. G. miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med. 2008, 6, 14.
157. Guo, C.; Sah, J. F.; Beard, L.; Willson, J. K.; Markowitz, S. D.; Guda, K. The noncoding RNA, miR-126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3-kinase signaling and is frequently lost in colon cancers. Genes Chromosomes Cancer 2008, 47 (11), 939-946.
158. Tavazoie, S. F.; Alarcon, C.; Oskarsson, T.; Padua, D.; Wang, Q.; Bos, P. D.; Gerald, W. L.; Massague, J. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008, 451 (7175), 147-152.
159. Sun, F.; Fu, H.; Liu, Q.; Tie, Y.; Zhu, J.; Xing, R.; Sun, Z.; Zheng, X. Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle arrest. FEBS Lett. 2008, 582 (10), 1564-1568.
160. Tazawa, H.; Tsuchiya, N.; Izumiya, M.; Nakagama, H. Tumorsuppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc. Natl. Acad. Sci. U.S.A. 2007, 104 (39), 15472-15477.
161. Kuehbacher, A.; Urbich, C.; Dimmeler, S. Targeting microRNA expression to regulate angiogenesis. Trends Pharmacol. Sci. 2008, 29 (1), 12-15.
162. Kasinski, A. L.; Slack, F. J. miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma. Cancer Res. 2012, 72 (21), 5576-5587.
163. Bueno, M. J.; Perez de Castro, I.; Malumbres, M. Control of cell proliferation pathways by microRNAs. Cell Cycle 2008, 7 (20), 3143-3148.
164. Kasinski, A. L.; Slack, F. J. Potential microRNA therapies targeting Ras, NFkappaB and p53 signaling. Curr. Opin. Mol. Ther. 2010, 12 (2), 147-157.
165. Salajegheh, A.; Pakneshan, S.; Rahman, A.; Dolan-Evans, E.; Zhang, S.; Kwong, E.; Gopalan, V.; Lo, C. Y.; Smith, R. A.; Lam, A. K. Co-regulatory potential of vascular endothelial growth factor-A and vascular endothelial growth factor-C in thyroid carcinoma. Hum. Pathol. 2013, 44 (10), 2204-2212.